• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Show Coverage: Delivery models must transform

Article

Collaboration is the driving force behind accountable care organizations (ACOs), a strategy that requires a partnership among a diverse set of stakeholders?providers, payers and purchasers.

Collaboration is the driving force behind accountable care organizations (ACOs), a strategy that requires a partnership among a diverse set of stakeholders–providers, payers and purchasers.

“ACOs represent a model offering the opportunity for the three constituents to reduce costs and improve quality, a concept that moves away from a fragmented fee–for–service environment and payment for volume of services to one with shared risk and savings and outcomes–based care,” said Bill Shea, partner, Healthcare Business Consulting for Cognizant, one of the panelists at a Thursday session on delivery model transformation.

Although a perspective from another important partner in an ACO-the hospital-was missing from the discussion, Shea said that these providers often serve as key facilitators in developing an ACO and are able to bend the trend through collaboration.

Panelists explored the operational elements of an ACO, including financial, organizational, care management and approaches to information technology.

“We need to develop the appropriate business structure to manage significant risk and align incentives among all parties,” he said. “By doing so, we anticipate a 0% spend trend, which early evidence has supported.”

At the heart of the ACO is the ability to integrate resources and information to provide care across the entire outpatient and inpatient spectrum–supporting outcomes–based payment systems, developing patient registries and master patient indexes and feeding the electronic medical record.

Shea isn’t convinced, however, that ACOs necessarily will hit a home run on their first step up to the plate.

“Information technology and developing the ACO infrastructure might very well stand in the way of the new models,” he said.

Shea also pointed to the challenge of assigning specific populations to ACOs, which can be critical in delivering on managed care concepts that have worked, providing population health and lowering variability of care among providers.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.